ST百灵：治疗糖尿病中药制剂专利申请获受理

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. (ST BaiLing) has applied for a national confidential patent for a traditional Chinese medicine formulation, "Tang Ning Tong Luo," aimed at treating diabetes and its complications, marking a significant milestone in the field of traditional Chinese medicine [1][2] Group 1: Company Developments - The confidential patent application for "Tang Ning Tong Luo" has been accepted by the National Intellectual Property Administration, highlighting the research achievements of the company [1] - "Tang Ning Tong Luo" is the first traditional Chinese medicine formulation in China to receive a confidential patent application, indicating its unique value in treating type 2 diabetes and its complications [2] - The patent protection will cover a range of conditions related to diabetes, including diabetic retinopathy, diabetic foot disease, erectile dysfunction associated with diabetes, and diabetic kidney disease, providing comprehensive protection throughout the disease cycle [2] Group 2: Industry Context - Diabetes has become a major public health challenge globally, with the International Diabetes Federation (IDF) reporting that by 2024, there will be 589 million diabetes patients aged 20-79 worldwide, with China having the highest number at 148 million [1] - The global market for diabetes treatment drugs is substantial, yet the core areas are still dominated by foreign manufacturers, and effective treatment options for complications remain scarce [1]